Skip to main content
. 2023 Jul 22;4(4):e337. doi: 10.1002/mco2.337

FIGURE 7.

FIGURE 7

Ubiquitin‐specific protease 5 (USP5) is upregulated and associated with poor survival in hepatocellular carcinoma (HCC). (A) USP5 mRNA expression levels in HCC samples (n = 374) and normal liver tissues (n = 50) were analyzed using the Cancer Genome Atlas (TCGA). (B) In six pairs of HCC tissues and normal liver tissues, USP5 protein expression levels were detected using western blot. (C) Immunohistochemistry (IHC) test of USP5 protein expression in 10 pairs of clinical samples (magnification, ×100, scale bar = 200 μm; magnification, ×200, scale bar = 100 μm; magnification, ×400, scale bar = 50 μm). (D) The expression of USP5 in TCGA liver HCC (LIHC) based on tumor grade (n = 374). (E) According to USP5 and lymphoid‐specific helicase (LSH) expression, the TCGA LIHC samples’ overall survival rate is represented by a Kaplan–Meier curve (n = 367). (F) A working model of deubiquitination of LSH by USP5 in inhibiting ferroptosis drawn by PowerPoint. USP5 inhibits ferroptosis through the stabilization of LSH in a deubiquitinase (DUB)‐dependent manner. Moreover, the increased LSH regulates the expression of ferroptosis‐related proteins. And the ability of USP5 to stabilize LSH can be inhibited by degrasyn. ***p < 0.001 and ****p < 0.0001.